Cannabis Use Is Associated With Increased Levels of Soluble gp130 in Schizophrenia but Not in Bipolar Disorder
The complex effects of plant cannabinoids on human physiology is not yet fully understood, but include a wide spectrum of effects on immune modulation. The immune system and its inflammatory effector pathways are recently emerging as possible causative factors in psychotic disorders. The present stu...
| Main Authors: | , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2020-07-01
|
| Series: | Frontiers in Psychiatry |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/article/10.3389/fpsyt.2020.00642/full |
| _version_ | 1819010911070846976 |
|---|---|
| author | Attila Szabo Attila Szabo Ibrahim A. Akkouh Ibrahim A. Akkouh Thor Ueland Trine Vik Lagerberg Ingrid Dieset Thomas Bjella Pål Aukrust Pål Aukrust Pål Aukrust Pål Aukrust Stephanie Le Hellard Stephanie Le Hellard Anne-Kristin Stavrum Anne-Kristin Stavrum Ingrid Melle Ole A. Andreassen Srdjan Djurovic Srdjan Djurovic |
| author_facet | Attila Szabo Attila Szabo Ibrahim A. Akkouh Ibrahim A. Akkouh Thor Ueland Trine Vik Lagerberg Ingrid Dieset Thomas Bjella Pål Aukrust Pål Aukrust Pål Aukrust Pål Aukrust Stephanie Le Hellard Stephanie Le Hellard Anne-Kristin Stavrum Anne-Kristin Stavrum Ingrid Melle Ole A. Andreassen Srdjan Djurovic Srdjan Djurovic |
| author_sort | Attila Szabo |
| collection | DOAJ |
| description | The complex effects of plant cannabinoids on human physiology is not yet fully understood, but include a wide spectrum of effects on immune modulation. The immune system and its inflammatory effector pathways are recently emerging as possible causative factors in psychotic disorders. The present study aimed to investigate whether self-administered Cannabis use was associated with changes in circulating immune and neuroendocrine markers in schizophrenia (SCZ) and bipolar disorder (BD) patients. A screening of 13 plasma markers reflecting different inflammatory pathways was performed in SCZ (n = 401) and BD patients (n = 242) after subdividing each group into Cannabis user and non-user subgroups. We found that i) soluble gp130 (sgp130) concentrations were significantly elevated among Cannabis users in the SCZ group (p = 0.002) after multiple testing correction, but not in BD. ii) Nominally significant differences were observed in the levels of IL-1RA (p = 0.0059), YKL40 (p = 0.0069), CatS (p = 0.013), sTNFR1 (p = 0.031), and BDNF (p = 0.020), where these factors exhibited higher plasma levels in Cannabis user SCZ patients than in non-users. iii) These differences in systemic levels were not reflected by altered mRNA expression of genes encoding sgp130, IL-1RA, YKL40, CatS, sTNFR1, and BDNF in whole blood. Our results show that Cannabis self-administration is associated with markedly higher sgp130 levels in SCZ, but not in BD, and that this phenomenon is independent of the modulation of peripheral immune cells. These findings warrant further investigation into the potential IL-6 trans-signaling modulatory, anti-inflammatory, neuroimmune, and biobehavioral-cognitive effects of Cannabis use in SCZ. |
| first_indexed | 2024-12-21T01:19:47Z |
| format | Article |
| id | doaj.art-701872f5c7cc48f38edbfcfda2922537 |
| institution | Directory Open Access Journal |
| issn | 1664-0640 |
| language | English |
| last_indexed | 2024-12-21T01:19:47Z |
| publishDate | 2020-07-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Psychiatry |
| spelling | doaj.art-701872f5c7cc48f38edbfcfda29225372022-12-21T19:20:42ZengFrontiers Media S.A.Frontiers in Psychiatry1664-06402020-07-011110.3389/fpsyt.2020.00642519125Cannabis Use Is Associated With Increased Levels of Soluble gp130 in Schizophrenia but Not in Bipolar DisorderAttila Szabo0Attila Szabo1Ibrahim A. Akkouh2Ibrahim A. Akkouh3Thor Ueland4Trine Vik Lagerberg5Ingrid Dieset6Thomas Bjella7Pål Aukrust8Pål Aukrust9Pål Aukrust10Pål Aukrust11Stephanie Le Hellard12Stephanie Le Hellard13Anne-Kristin Stavrum14Anne-Kristin Stavrum15Ingrid Melle16Ole A. Andreassen17Srdjan Djurovic18Srdjan Djurovic19NORMENT, Institute of Clinical Medicine, University of Oslo, and Division of Mental Health and Addiction, Oslo University Hospital, Oslo, NorwayDepartment of Medical Genetics, Oslo University Hospital, Oslo, NorwayNORMENT, Institute of Clinical Medicine, University of Oslo, and Division of Mental Health and Addiction, Oslo University Hospital, Oslo, NorwayDepartment of Medical Genetics, Oslo University Hospital, Oslo, NorwayNORMENT, Institute of Clinical Medicine, University of Oslo, and Division of Mental Health and Addiction, Oslo University Hospital, Oslo, NorwayNORMENT, Institute of Clinical Medicine, University of Oslo, and Division of Mental Health and Addiction, Oslo University Hospital, Oslo, NorwayNORMENT, Institute of Clinical Medicine, University of Oslo, and Division of Mental Health and Addiction, Oslo University Hospital, Oslo, NorwayNORMENT, Institute of Clinical Medicine, University of Oslo, and Division of Mental Health and Addiction, Oslo University Hospital, Oslo, NorwayResearch Institute of Internal Medicine, Oslo University Hospital Rikshospitalet, Oslo, NorwaySection of Clinical Immunology and Infectious Diseases, Oslo University Hospital, Rikshospitalet, Oslo, NorwayK.G. Jebsen Inflammatory Research Center, University of Oslo, Oslo, NorwayK.G. Jebsen Thrombosis Research and Expertise Center, University of Tromsø, Tromsø, NorwayNORMENT, Department of Clinical Science, University of Bergen, Bergen, NorwayCenter for Medical Genetics and Molecular Medicine, Haukeland University Hospital, Bergen, NorwayNORMENT, Department of Clinical Science, University of Bergen, Bergen, NorwayCenter for Medical Genetics and Molecular Medicine, Haukeland University Hospital, Bergen, NorwayNORMENT, Institute of Clinical Medicine, University of Oslo, and Division of Mental Health and Addiction, Oslo University Hospital, Oslo, NorwayNORMENT, Institute of Clinical Medicine, University of Oslo, and Division of Mental Health and Addiction, Oslo University Hospital, Oslo, NorwayDepartment of Medical Genetics, Oslo University Hospital, Oslo, NorwayNORMENT, Department of Clinical Science, University of Bergen, Bergen, NorwayThe complex effects of plant cannabinoids on human physiology is not yet fully understood, but include a wide spectrum of effects on immune modulation. The immune system and its inflammatory effector pathways are recently emerging as possible causative factors in psychotic disorders. The present study aimed to investigate whether self-administered Cannabis use was associated with changes in circulating immune and neuroendocrine markers in schizophrenia (SCZ) and bipolar disorder (BD) patients. A screening of 13 plasma markers reflecting different inflammatory pathways was performed in SCZ (n = 401) and BD patients (n = 242) after subdividing each group into Cannabis user and non-user subgroups. We found that i) soluble gp130 (sgp130) concentrations were significantly elevated among Cannabis users in the SCZ group (p = 0.002) after multiple testing correction, but not in BD. ii) Nominally significant differences were observed in the levels of IL-1RA (p = 0.0059), YKL40 (p = 0.0069), CatS (p = 0.013), sTNFR1 (p = 0.031), and BDNF (p = 0.020), where these factors exhibited higher plasma levels in Cannabis user SCZ patients than in non-users. iii) These differences in systemic levels were not reflected by altered mRNA expression of genes encoding sgp130, IL-1RA, YKL40, CatS, sTNFR1, and BDNF in whole blood. Our results show that Cannabis self-administration is associated with markedly higher sgp130 levels in SCZ, but not in BD, and that this phenomenon is independent of the modulation of peripheral immune cells. These findings warrant further investigation into the potential IL-6 trans-signaling modulatory, anti-inflammatory, neuroimmune, and biobehavioral-cognitive effects of Cannabis use in SCZ.https://www.frontiersin.org/article/10.3389/fpsyt.2020.00642/fullCannabisimmune modulationsgp130IL-6 trans-signalingschizophreniabipolar disorder |
| spellingShingle | Attila Szabo Attila Szabo Ibrahim A. Akkouh Ibrahim A. Akkouh Thor Ueland Trine Vik Lagerberg Ingrid Dieset Thomas Bjella Pål Aukrust Pål Aukrust Pål Aukrust Pål Aukrust Stephanie Le Hellard Stephanie Le Hellard Anne-Kristin Stavrum Anne-Kristin Stavrum Ingrid Melle Ole A. Andreassen Srdjan Djurovic Srdjan Djurovic Cannabis Use Is Associated With Increased Levels of Soluble gp130 in Schizophrenia but Not in Bipolar Disorder Frontiers in Psychiatry Cannabis immune modulation sgp130 IL-6 trans-signaling schizophrenia bipolar disorder |
| title | Cannabis Use Is Associated With Increased Levels of Soluble gp130 in Schizophrenia but Not in Bipolar Disorder |
| title_full | Cannabis Use Is Associated With Increased Levels of Soluble gp130 in Schizophrenia but Not in Bipolar Disorder |
| title_fullStr | Cannabis Use Is Associated With Increased Levels of Soluble gp130 in Schizophrenia but Not in Bipolar Disorder |
| title_full_unstemmed | Cannabis Use Is Associated With Increased Levels of Soluble gp130 in Schizophrenia but Not in Bipolar Disorder |
| title_short | Cannabis Use Is Associated With Increased Levels of Soluble gp130 in Schizophrenia but Not in Bipolar Disorder |
| title_sort | cannabis use is associated with increased levels of soluble gp130 in schizophrenia but not in bipolar disorder |
| topic | Cannabis immune modulation sgp130 IL-6 trans-signaling schizophrenia bipolar disorder |
| url | https://www.frontiersin.org/article/10.3389/fpsyt.2020.00642/full |
| work_keys_str_mv | AT attilaszabo cannabisuseisassociatedwithincreasedlevelsofsolublegp130inschizophreniabutnotinbipolardisorder AT attilaszabo cannabisuseisassociatedwithincreasedlevelsofsolublegp130inschizophreniabutnotinbipolardisorder AT ibrahimaakkouh cannabisuseisassociatedwithincreasedlevelsofsolublegp130inschizophreniabutnotinbipolardisorder AT ibrahimaakkouh cannabisuseisassociatedwithincreasedlevelsofsolublegp130inschizophreniabutnotinbipolardisorder AT thorueland cannabisuseisassociatedwithincreasedlevelsofsolublegp130inschizophreniabutnotinbipolardisorder AT trineviklagerberg cannabisuseisassociatedwithincreasedlevelsofsolublegp130inschizophreniabutnotinbipolardisorder AT ingriddieset cannabisuseisassociatedwithincreasedlevelsofsolublegp130inschizophreniabutnotinbipolardisorder AT thomasbjella cannabisuseisassociatedwithincreasedlevelsofsolublegp130inschizophreniabutnotinbipolardisorder AT palaukrust cannabisuseisassociatedwithincreasedlevelsofsolublegp130inschizophreniabutnotinbipolardisorder AT palaukrust cannabisuseisassociatedwithincreasedlevelsofsolublegp130inschizophreniabutnotinbipolardisorder AT palaukrust cannabisuseisassociatedwithincreasedlevelsofsolublegp130inschizophreniabutnotinbipolardisorder AT palaukrust cannabisuseisassociatedwithincreasedlevelsofsolublegp130inschizophreniabutnotinbipolardisorder AT stephanielehellard cannabisuseisassociatedwithincreasedlevelsofsolublegp130inschizophreniabutnotinbipolardisorder AT stephanielehellard cannabisuseisassociatedwithincreasedlevelsofsolublegp130inschizophreniabutnotinbipolardisorder AT annekristinstavrum cannabisuseisassociatedwithincreasedlevelsofsolublegp130inschizophreniabutnotinbipolardisorder AT annekristinstavrum cannabisuseisassociatedwithincreasedlevelsofsolublegp130inschizophreniabutnotinbipolardisorder AT ingridmelle cannabisuseisassociatedwithincreasedlevelsofsolublegp130inschizophreniabutnotinbipolardisorder AT oleaandreassen cannabisuseisassociatedwithincreasedlevelsofsolublegp130inschizophreniabutnotinbipolardisorder AT srdjandjurovic cannabisuseisassociatedwithincreasedlevelsofsolublegp130inschizophreniabutnotinbipolardisorder AT srdjandjurovic cannabisuseisassociatedwithincreasedlevelsofsolublegp130inschizophreniabutnotinbipolardisorder |